Topline Capital Management LLC Takes Position in Quanterix Corporation $QTRX

Key Points

• Topline Capital Management LLC acquired 386,037 shares of Quanterix Corporation valued at approximately $2.5 million, making it the firm's 28th largest position.
• Insider transactions included Director David R. Walt purchasing 131,869 shares at $5.43 each, increasing his stake in Quanterix by 8.81%.
• Quanterix reported losses of $0.47 earnings per share for the last quarter, falling short of the consensus estimate, and has set its FY 2025 guidance on earnings per share.

Topline Capital Management LLC bought a new position in Quanterix Corporation (NASDAQ:QTRX - Free Report) in the first quarter, according to its most recent filing with the SEC. The firm bought 386,037 shares of the company's stock, valued at approximately $2,513,000. Quanterix makes up 0.6% of Topline Capital Management LLC's investment portfolio, making the stock its 28th largest position. Topline Capital Management LLC owned 1.00% of Quanterix as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its stake in Quanterix by 219.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company's stock worth $61,000 after purchasing an additional 3,915 shares in the last quarter. Quantbot Technologies LP boosted its stake in Quanterix by 245.9% in the 1st quarter. Quantbot Technologies LP now owns 11,272 shares of the company's stock worth $73,000 after purchasing an additional 8,013 shares in the last quarter. Aaron Wealth Advisors LLC acquired a new stake in Quanterix in the 1st quarter worth approximately $79,000. Allspring Global Investments Holdings LLC acquired a new stake in Quanterix in the 1st quarter worth approximately $98,000. Finally, ProShare Advisors LLC acquired a new stake in Quanterix in the 4th quarter worth approximately $108,000. 86.48% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director David R. Walt purchased 123,990 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were purchased at an average price of $6.14 per share, with a total value of $761,298.60. Following the purchase, the director owned 1,866,933 shares of the company's stock, valued at $11,462,968.62. The trade was a 7.11% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William P. Donnelly bought 93,113 shares of the stock in a transaction on Friday, June 6th. The shares were acquired at an average cost of $5.44 per share, for a total transaction of $506,534.72. Following the purchase, the director owned 139,094 shares in the company, valued at $756,671.36. The trade was a 202.50% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased a total of 463,113 shares of company stock worth $2,625,444 in the last three months. 6.80% of the stock is owned by corporate insiders.

Quanterix Stock Down 2.1%

Shares of NASDAQ:QTRX traded down $0.10 during trading on Tuesday, hitting $4.46. 251,418 shares of the stock traded hands, compared to its average volume of 781,597. The company has a market cap of $207.02 million, a price-to-earnings ratio of -2.45 and a beta of 1.03. The company has a fifty day moving average price of $5.59 and a two-hundred day moving average price of $5.93. Quanterix Corporation has a 52-week low of $4.05 and a 52-week high of $15.85.

Quanterix (NASDAQ:QTRX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.06). Quanterix had a negative net margin of 56.04% and a negative return on equity of 18.41%. The firm had revenue of $24.48 million for the quarter, compared to analysts' expectations of $29.73 million. Quanterix has set its FY 2025 guidance at EPS. On average, equities research analysts predict that Quanterix Corporation will post -0.98 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Canaccord Genuity Group reiterated a "hold" rating and issued a $5.00 target price (down from $12.00) on shares of Quanterix in a research note on Monday, August 11th. Wall Street Zen lowered shares of Quanterix from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, Quanterix has a consensus rating of "Hold" and a consensus target price of $11.75.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.